Literature DB >> 21452856

Carbon isotopes profiles of human whole blood, plasma, red blood cells, urine and feces for biological/biomedical 14C-accelerator mass spectrometry applications.

Seung-Hyun Kim1, Jennifer C Chuang, Peter B Kelly, Andrew J Clifford.   

Abstract

Radiocarbon ((14)C) is an ideal tracer for in vivo human ADME (absorption, distribution, metabolism, elimination) and PBPK (physiological-based pharmacokinetic) studies. Living plants peferentially incorporate atmospheric (14)CO(2) versus (13)CO(2) versus (12)CO(2), which result in unique signature. Furthermore, plants and the food chains they support also have unique carbon isotope signatures. Humans, at the top of the food chain, consequently acquire isotopic concentrations in the tissues and body fluids depending on their dietary habits. In preparation of ADME and PBPK studies, 12 healthy subjects were recruited. The human baseline (specific to each individual and their diet) total carbon (TC) and carbon isotope (13)C (δ(13)C) and (14)C (F(m)) were quantified in whole blood (WB), plasma, washed red blood cell (RBC), urine, and feces. TC (mg of C/100 μL) in WB, plasma, RBC, urine, and feces were 11.0, 4.37, 7.57, 0.53, and 1.90, respectively. TC in WB, RBC, and feces was higher in men over women, P < 0.05. Mean δ(13)C were ranked low to high as follows: feces < WB = plasma = RBC = urine, P < 0.0001. δ(13)C was not affected by gender. Our analytic method shifted δ(13)C by only ±1.0 ‰ ensuring our F(m) measurements were accurate and precise. Mean F(m) were ranked low to high as follows: plasma = urine < WB = RBC = feces, P < 0.05. F(m) in feces was higher for men over women, P < 0.05. Only in WB, (14)C levels (F(m)) and TC were correlated with one another (r = 0.746, P < 0.01). Considering the lag time to incorporate atmospheric (14)C into plant foods (vegetarian) and or then into animal foods (nonvegetarian), the measured F(m) of WB in our population (recruited April 2009) was 1.0468 ± 0.0022 (mean ± SD), and the F(m) of WB matched the (extrapolated) atmospheric F(m) of 1.0477 in 2008. This study is important in presenting a procedure to determine a baseline for a study group for human ADME and PBPK studies using (14)C as a tracer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21452856      PMCID: PMC3086998          DOI: 10.1021/ac103038s

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  25 in total

1.  Intrinsic erythrocyte labeling and attomole pharmacokinetic tracing of 14C-labeled folic acid with accelerator mass spectrometry.

Authors:  B A Buchholz; A Arjomand; S R Dueker; P D Schneider; A J Clifford; J S Vogel
Journal:  Anal Biochem       Date:  1999-05-01       Impact factor: 3.365

2.  Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.

Authors:  Graham Lappin; Wilhelm Kuhnz; Roeline Jochemsen; Johannes Kneer; Ajai Chaudhary; Berend Oosterhuis; Willem Jan Drijfhout; Malcolm Rowland; R Colin Garner
Journal:  Clin Pharmacol Ther       Date:  2006-09       Impact factor: 6.875

3.  The phase 0 microdosing concept.

Authors:  R Colin Garner; Graham Lappin
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

4.  Subattomole sensitivity in biological accelerator mass spectrometry.

Authors:  Mehran Salehpour; Göran Possnert; Helge Bryhni
Journal:  Anal Chem       Date:  2008-04-19       Impact factor: 6.986

5.  Bomb 14 C in the human population.

Authors:  R Nydal; K Lövseth; O Syrstad
Journal:  Nature       Date:  1971-08-06       Impact factor: 49.962

Review 6.  Applications of accelerator mass spectrometry for pharmacological and toxicological research.

Authors:  Karen Brown; Elaine M Tompkins; Ian N H White
Journal:  Mass Spectrom Rev       Date:  2006 Jan-Feb       Impact factor: 10.946

7.  Accelerator mass spectrometry analysis of background (14)C-concentrations in human blood: aiming at reference data for further microdosing studies.

Authors:  Ryogo Minamimoto; Yoshimi Hamabe; Teiji Miyaoka; Takamitsu Hara; Keisuke Yoshida; Takashi Oka; Tomio Inoue
Journal:  Ann Nucl Med       Date:  2009-01-08       Impact factor: 2.668

8.  Quantitation of in vivo human folate metabolism.

Authors:  Yumei Lin; Stephen R Dueker; Jennifer R Follett; James G Fadel; Ali Arjomand; Philip D Schneider; Joshua W Miller; Ralph Green; Bruce A Buchholz; John S Vogel; Robert D Phair; Andrew J Clifford
Journal:  Am J Clin Nutr       Date:  2004-09       Impact factor: 7.045

9.  Age-related variation in red blood cell stable isotope ratios (delta13C and delta15N) from two Yupik villages in southwest Alaska: a pilot study.

Authors:  Michael J Wilkinson; Youlim Yai; Diane M O'Brien
Journal:  Int J Circumpolar Health       Date:  2007-02       Impact factor: 1.228

10.  Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA.

Authors:  K W Turteltaub; J S Felton; B L Gledhill; J S Vogel; J R Southon; M W Caffee; R C Finkel; D E Nelson; I D Proctor; J C Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

View more
  1 in total

1.  A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.

Authors:  Neeraj Gupta; Steven Zhang; Sandeepraj Pusalkar; Mihaela Plesescu; Swapan Chowdhury; Michael J Hanley; Bingxia Wang; Cindy Xia; Xiaoquan Zhang; Karthik Venkatakrishnan; Dale R Shepard
Journal:  Invest New Drugs       Date:  2017-09-21       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.